Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

With nearly half of Americans saying weight loss is a goal for them, it’s no wonder that interest in GLP-1 medications has ...

One in eight. That's how many people living in the United States have taken some form of a glucagon-like peptide 1, otherwise known as a GLP-1, medication for weight loss and related conditions ...

GLP-1, or glucagon-like peptide-1, is a hormone produced in the digestive system that regulates appetite and insulin secretion. Medications like Ozempic and Wegovy, categorized as GLP-1 agonists ...

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

While IPA has strategically aligned its therapies with an established nucleic acid delivery technology, its AI-driven approach has tailored the genetic sequences ... peptide discovery pipeline, the ...

Verdiva said this drug could also be used as a monotherapy or in combination with a proprietary GLP-1 peptide drug. Other companies are also developing amylin-targeting drugs. Novo Nordisk’s ...